Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer

Дата публикации: 23-10-2026 00:00:00

Antibody-drug conjugates (ADCs) combine the tumor-targeting specificity of a monoclonal antibody with a cytotoxic payload, using a chemical linker designed to remain stable in the bloodstream and to release the drug selectively within tumor cells. Third-generation ADCs can exert a bystander effect, whereby the payload diffuses into neighboring tumor cells, killing them independently of target expression. The drug to antibody ratio further modulates potency and tolerability. ADCs have transformed the life expectancy of patients with erythroblastic oncogene B (ERBB2; formerly HER2/neu)–overexpressing breast cancer and are rapidly expanding into new tumor types and molecular subgroups.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer	0	15.98	23-10-2026
2	Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer Research Summary	0	12.56	23-10-2026
3	This new antibody may stop one of the deadliest breast cancers	0	8.13	23-01-2026
4	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
5	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
6	EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan	0	5	26-06-2026
7	A hidden immune backup system could supercharge mRNA cancer vaccines	0	9.29	09-07-2026
8	Disitamab Vedotin Plus Tislelizumab in Non–Muscle-Invasive Bladder Cancer	0	13.81	08-10-2026
9	FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers	8	7	30-06-2026
10	How aggressive breast cancer turns off the immune system	0	5.76	12-04-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.5. Источник: www.jamanetwork.com.